Patents by Inventor Martin VALIK

Martin VALIK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230278990
    Abstract: The present disclosure relates to solid state forms of Encequidar and Encequidar mesylate, processes for their preparation, and pharmaceutical compositions thereof.
    Type: Application
    Filed: July 9, 2021
    Publication date: September 7, 2023
    Inventors: Pavel Kolesa, Miroslav Vavrecka, Roman Gabriel, Martin Valík
  • Publication number: 20210300950
    Abstract: The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.
    Type: Application
    Filed: June 14, 2021
    Publication date: September 30, 2021
    Inventors: Martin VALIK, Roman GABRIEL, Pavel VRASPIR, David LUKAS
  • Patent number: 11053261
    Abstract: The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: July 6, 2021
    Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
    Inventors: Martin Valik, Roman Gabriel, Pavel Vraspir, David Lukas
  • Publication number: 20200190119
    Abstract: The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 18, 2020
    Inventors: Martin VALIK, Roman GABRIEL, Pavel VRASPIR, David LUKAS
  • Patent number: 10604537
    Abstract: The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: March 31, 2020
    Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
    Inventors: Martin Valik, Roman Gabriel, Pavel Vraspir, David Lukas
  • Publication number: 20190330243
    Abstract: The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.
    Type: Application
    Filed: June 8, 2017
    Publication date: October 31, 2019
    Inventors: Martin VALIK, Roman GABRIEL, Pavel VRASPIR, David LUKAS
  • Publication number: 20090292131
    Abstract: A paclitaxel intermediate of formula 1: wherein R1 is acetyl, R2 is tert-butyloxycarbonyl (BOC), R3 and R4 are phenyl and R5 is 1-ethoxyethyl, is provided. Also provided are processes for preparing taxane intermediates of formula 1 comprising reacting a compound of formula 2 with a compound of formula 3 wherein, R1, R2 and R5 are independently a hydroxyl protecting group; R3 is phenyl, substituted phenyl, a straight or branched alkyl containing 1 to 12 carbon atoms, alkenyl containing 2 to 12 carbon atoms, cycloalkyl containing 4 to 15 carbon atoms, cycloalkenyl or an R6—O— group in which R6 is: phenyl, substituted phenyl group, a C1-C8 straight or branched alkyl, a C2-C8 straight or branched alkenyl group, a C3-C8 straight or branched alkynyl, a C3-C7 cycloalkyl, C4-C7 cycloalkenyl, a C7-C11 bicycloalkyl substituent, or a saturated or unsaturated nitrogen; and R4 is phenyl or a substituted phenyl group.
    Type: Application
    Filed: May 6, 2009
    Publication date: November 26, 2009
    Inventors: Ladislav CVAK, Martin VALIK, Tomás HOLAS, Jirí MALECEK